Multispecific innovation designed for collaboration.
Pharmaceutical companies increasingly seek innovative biologic technologies that can improve existing drugs or generate new therapies.
Imunexus provides these opportunities through its multispecific biologics platform and growing pipeline of drug candidates.
The imunexin ™ platform can be integrated with existing biologic drugs, enabling partners to create differentiated therapies while generating new intellectual property.
These models allow Imunexus to work with partners to develop innovative biologic medicines.
We would be pleased to provide a non-confidential presentation to companies expressing further interest in partnerships.
